Every 8-K that Ekso Bionics Holdings, Inc. (EKSO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EKSO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EKSO filings page.
ChronoScale Corporation announced that its Board approved a plan on May 29, 2026 to divest its wholly owned subsidiary, Ekso Bionics, Inc., and concentrate operations solely on its cloud business.
The company expects to complete the Ekso divestiture during the first fiscal quarter. It anticipates material charges related to severance costs, lease termination payments, transaction expenses, and other exit costs. ChronoScale has not yet determined reliable estimates for these charges and plans to amend the report within four business days after setting those estimates, as required.
ChronoScale Corporation, formerly Ekso Bionics Holdings, Inc., is amending previously disclosed phantom performance-based stock unit awards for three senior executives. The awards, granted on November 5, 2025, totaled 185,000 Phantom PSUs for Scott G. Davis, 40,000 for Jerome Wong, and 32,000 for Jason Jones.
The Board determined on May 14, 2026 that the stock price goal was achieved and that the May 5, 2026 closing of a Contribution and Exchange Agreement constituted a Change in Control, satisfying vesting conditions. Settlement has been changed from cash-only to equity and cash.
Mr. Davis’s award will now settle in 109,357 shares of common stock plus a $1,000,000 cash payment, while Mr. Wong and Mr. Jones will receive 40,000 and 32,000 shares of common stock, respectively. Payments and share issuances will occur after the closing and no later than March 15, 2027.
ChronoScale Corporation, formerly Ekso Bionics Holdings, completed its business combination with Applied Digital’s cloud subsidiary, Applied Digital Cloud Corporation, which is now a wholly owned subsidiary. The company also changed its name, fiscal year-end to May 31, and Nasdaq ticker to CHRN.
Contributor received 138,216,820 new common shares in exchange for all Cloud equity, and Applied Digital purchased 1,311,407 common shares for approximately $15.75 million in a private PIPE at $12.01 per share. After closing, Applied Digital and Contributor hold about 97% of outstanding common stock, leaving legacy Ekso holders with about 3% of 143,093,381 shares outstanding.
An Investor Rights Agreement gives Applied-related holders extensive board designation, observer, approval, preemptive and registration rights, while a services agreement entitles Applied Digital to a quarterly fee equal to 1% of ChronoScale’s gross revenue. The company adopted a 22,500,000-share 2026 Omnibus Equity Incentive Plan and appointed Ying Cenly Chen as CEO under a new offer letter, while changing auditors from WithumSmith+Brown to CBIZ CPAs.
Ekso Bionics Holdings, Inc. outlines the final steps to close its previously announced business combination with Applied Digital affiliates under a Contribution and Exchange Agreement, after which the company will be renamed ChronoScale Corporation and its stock is expected to trade on Nasdaq under the symbol “CHRN.”
As a condition to closing, Ekso entered into a Securities Purchase Agreement with Applied Digital Corporation for the APLD Parent PIPE Investment, selling 1,311,407 common shares at $12.01 per share for gross proceeds of about $15.75 million. Lake Street Capital Markets will receive a 5.0% cash fee, roughly $0.75 million, for placement services. The company also filed Second Amended and Restated Articles of Incorporation with effectiveness timed around the May 5, 2026 closing sequence.
Ekso Bionics Holdings, Inc. plans a transformative business combination with Applied Digital’s cloud subsidiary. Ekso will acquire 100% of Applied Digital Cloud Corporation in exchange for issuing 138,216,820 new common shares to APLD’s Contributor entity, which is expected to own about 97% of the combined company’s equity at closing. Ekso will be renamed ChronoScale Corporation and must maintain at least $15,000,000 in cash and cash equivalents, inclusive of PIPE proceeds, for closing. The parties expect the transaction to close in the second calendar quarter of 2026, subject to stockholder approval, regulatory clearances, a PIPE financing and Nasdaq listing approval.
The Second Amended and Restated Articles will increase authorized common shares from 141,428,571 to 290,000,000 and tighten director removal to for-cause only with a 75% voting threshold. A new 2026 Omnibus Equity Incentive Plan will authorize 22,500,000 shares for awards, effective at closing and subject to stockholder approval.
Ekso Bionics Holdings, Inc. entered into securities purchase agreements for a private placement of 5,852 shares of newly created Series B Convertible Preferred Stock, each with a stated value of $1,000, convertible into an aggregate of 711,922 shares of common stock at $8.22 per share, and Warrants to purchase up to 355,960 additional common shares at the same exercise price. The transaction closed on January 22, 2026 and is expected to generate approximately $5.3 million in net proceeds, which the company plans to use for working capital and general corporate purposes.
The company also agreed to register the resale of the conversion shares and warrant shares, with a filing deadline of June 1, 2026 and targeted effectiveness within 30–60 days afterward, depending on SEC review. The Series B Preferred Stock carries limited voting rights on an as-converted basis, conversion and warrant exercise caps at 9.99% per holder and 19.99% in the aggregate in certain cases, protective approval rights for key corporate actions, and is redeemable at the stated value at the option of the company or holders starting one year after closing, and upon certain trading failures.
Ekso Bionics Holdings approved new executive equity awards on November 5, 2025. Scott Davis, Jerome Wong, and Jason Jones received fully vested RSUs covering 80,000, 19,500, and 15,000 shares, respectively. Each also received cash‑settled Phantom PSUs covering 185,000, 40,000, and 32,000 notional shares that vest only if two conditions are met within five years: a Change in Control and a Stock Price of at least $7.50 as defined.
The company also entered into new Change in Control and Severance Agreements with each executive, replacing prior arrangements. If terminated outside a Change in Control, base salary continues for 6 months (or 9 months for Mr. Davis). If terminated within the Change in Control period (or upon Good Reason), severance includes a lump sum of 9 months base salary (or 18 months for Mr. Davis), COBRA premiums for the same periods, and full acceleration of time‑based equity awards. Payments require a release and include a 280G best‑net cutback provision.
Ekso Bionics Holdings, Inc. announced a registered direct offering of 769,490 shares of common stock at $4.81 per share. The company expects approximately $3.2 million in net proceeds after fees and expenses, with intended uses for general corporate purposes, including R&D, SG&A, strategic initiatives, and working capital. The transaction is expected to close on or about October 30, 2025, subject to customary closing conditions.
In connection with the offering, Ekso entered a placement agency agreement with Lake Street Capital Markets. The company will pay a cash fee equal to 6% of gross proceeds and issue a placement agent warrant to purchase up to 15,389 shares at an exercise price of $4.81 per share. The placement agent warrant was offered in reliance on Section 4(a)(2) and the shares issuable upon exercise have not been registered.
Ekso Bionics Holdings, Inc. furnished an update on its financial results for the three and nine months ended September 30, 2025. The company disclosed the results under Item 2.02 and attached a press release as Exhibit 99.1, which is incorporated by reference. The information is being furnished and is not deemed filed under the Exchange Act.
Ekso Bionics Holdings, Inc. entered a Secured Promissory Note and Security Agreement with B. Riley Commercial Capital, LLC providing a secured term loan facility of up to $2.0 million to be used for working capital and general corporate purposes. Borrowings accrue interest at 10.0% per annum payable at maturity and the company will owe an Exit Fee equal to 10% of original principal ($200,000) if the loan matures. The loan matures upon the earlier of a Qualified Financing raising $2.4 million net proceeds or September 14, 2026. The lender may convert outstanding obligations into equity in connection with a Qualified Financing. The obligations are guaranteed by Ekso Bionics, Inc. and secured by substantially all personal property, and the agreement includes customary covenants, events of default and a potential default interest of +5.0% per annum above the base rate. The company simultaneously repaid and terminated its prior $2.0 million loan agreement with Banc of California.